Access to advanced oncology treatments
China is rapidly developing new cellular therapies, targeted medicines and advanced radiotherapy techniques. For selected patients, this may provide access to treatment that is not yet available in Europe, is difficult to access or is considerably more expensive.
Evidence status: Highly indication-dependent; from established to experimentalWhat is the medical problem?
In advanced cancer, standard treatment lines may be exhausted while new registered or trial-based therapies are available elsewhere. The value therefore does not lie in saying that ‘China treats cancer better’, but in matching a specific tumour biology to a concrete therapy.
What could a treatment pathway look like?
The European oncology file, pathology, molecular markers and imaging are reviewed digitally in advance. Travel is planned only if a Chinese treatment team confirms in writing that the patient meets the inclusion criteria. Treatment is then followed by a complication plan and an English-language handover for European follow-up.
What do we know about effectiveness?
Evidence status varies by technique. Some CAR-T products and targeted medicines have regulated indications and clinical trial data. Proton and carbon-ion therapy are established radiotherapy technologies for selected indications. BNCT and some applications of HIFU or IRE remain indication-dependent or experimental. Each therapy must be assessed separately.
Important selection considerations
No oncology journey is offered without assessment of tumour type, stage, biomarkers, previous treatment lines, performance status and acute risks. Experimental treatment is clearly identified as experimental and must not delay standard potentially curative care.
Medical selection before travel
The options described are not a guarantee of treatment. Availability and suitability depend on diagnosis, indication, evidence level, individual risks and assessment by the treating medical team. Experimental care is identified as such.
Would you like to know whether a pathway could be medically appropriate?
A treatment journey always begins with an assessment of the diagnosis, medical history, previous treatments, medication, risks and the specific treatment objective.